Next Article in Journal
Noninvasive Subcellular Imaging Using Atomic Force Acoustic Microscopy (AFAM)
Next Article in Special Issue
Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
Previous Article in Journal
Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
Previous Article in Special Issue
Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?
Article

SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study

1
Liver Unit, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, Italy
2
Infectious Disease Unit, Ospedale “Galliera”, 16128 Genova, Italy
3
Biostatistics Unit, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, Italy
4
Infectious Disease Unit, Università di Bologna, 40126 Bologna, Italy
5
Infectious Disease Unit, University of Parma, 43125 Parma, Italy
6
Internal Medicine, Università del Piemonte Orientale, 28100 Novara, Italy
7
Gastroenterology Unit, Università di Torino, 10124 Torino, Italy
*
Author to whom correspondence should be addressed.
Cells 2019, 8(4), 313; https://doi.org/10.3390/cells8040313
Received: 7 March 2019 / Revised: 26 March 2019 / Accepted: 29 March 2019 / Published: 4 April 2019
(This article belongs to the Special Issue Hepatitis C Virus and Host Interactions)
In clinical trials, a sofosbuvir/velpatasvir (SOF/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. No real-life data on genotype 3 (GT3) cirrhotic patients with portal hypertension are available. The aim of this study was to assess the effectiveness of SOF/VEL in GT3 cirrhotics with portal hypertension. Patients with GT3 and advanced cirrhosis were treated for 12 weeks with SOF/VEL without ribavirin at five different centers in Italy from June 2017 to August 2018 and their SVR12 was assessed. Of the 227 GT3 cirrhotics evaluated, 205 met the inclusion criteria and 111 had transient elastography results ≥20 KPa. SVR12 was 97.6% (95% CI 94.4–98.9), rates were 99.1% (95% CI 95.7–99.8) in patients with ≥20 KPa and 95.8% (95% CI 89.5–98.3) in those with <20 KPa (p = 0.18). Analyzed by presence of esophageal varices, the SVR12 rates were 98.4% (95% CI 91.4–99.7) and 97.1% (95% CI 92.9–98.9) in patients without and with varices, respectively (p = 1.0). In real life, SOF/VEL GT3 cirrhotic patients with evidence of portal hypertension can achieve SVR12 levels comparable to those of patients without portal hypertension. These SVR12 rates are similar to what is reported in compensated cirrhosis treated within clinical trials. View Full-Text
Keywords: HCV; SOF/VEL; genotype 3; cirrhosis; portal hypertension HCV; SOF/VEL; genotype 3; cirrhosis; portal hypertension
Show Figures

Figure 1

MDPI and ACS Style

Mangia, A.; Cenderello, G.; Copetti, M.; Verucchi, G.; Piazzolla, V.; Lorusso, C.; Santoro, R.; Squillante, M.M.; Orlandini, A.; Minisini, R.; Ciancio, A. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. Cells 2019, 8, 313. https://doi.org/10.3390/cells8040313

AMA Style

Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. Cells. 2019; 8(4):313. https://doi.org/10.3390/cells8040313

Chicago/Turabian Style

Mangia, Alessandra, Giovanni Cenderello, Massimiliano Copetti, Gabriella Verucchi, Valeria Piazzolla, Celeste Lorusso, Rosanna Santoro, Maria M. Squillante, Alessandra Orlandini, Rosalba Minisini, and Alessia Ciancio. 2019. "SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study" Cells 8, no. 4: 313. https://doi.org/10.3390/cells8040313

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop